[
  {
    "ts": null,
    "headline": "Aon (AON): Exploring Shareholder Value After Recent Results and Long-Term Growth",
    "summary": "Aon (AON) shares have shown some movement lately, and it is catching the attention of investors interested in how insurance sector stocks are faring. The company’s recent quarterly results and long-term gains provide context for this shift. See our latest analysis for Aon. Aon’s share price has drifted modestly this year, but the bigger story comes from its resilience and steady long-term growth. The company’s 1-year total shareholder return of 6.6% highlights ongoing momentum, while its...",
    "url": "https://finnhub.io/api/news?id=f4c6d7dbd754e96eb8be15c12fa282d69a07baa35d8a623f4a6a2320b1d56eba",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759749498,
      "headline": "Aon (AON): Exploring Shareholder Value After Recent Results and Long-Term Growth",
      "id": 136989712,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AON",
      "source": "Yahoo",
      "summary": "Aon (AON) shares have shown some movement lately, and it is catching the attention of investors interested in how insurance sector stocks are faring. The company’s recent quarterly results and long-term gains provide context for this shift. See our latest analysis for Aon. Aon’s share price has drifted modestly this year, but the bigger story comes from its resilience and steady long-term growth. The company’s 1-year total shareholder return of 6.6% highlights ongoing momentum, while its...",
      "url": "https://finnhub.io/api/news?id=f4c6d7dbd754e96eb8be15c12fa282d69a07baa35d8a623f4a6a2320b1d56eba"
    }
  },
  {
    "ts": null,
    "headline": "Oculis Accelerates Privosegtor into Registrational Trials in Acute Optic Neuritis, Pioneering the Path for a Potential First-in-class Neuroprotective Therapy",
    "summary": "ZUG, Switzerland, Oct. 06, 2025 (GLOBE NEWSWIRE) -- Successful meeting with FDA enables advancement into pivotal development with Privosegtor in Acute Optic Neuritis (AON) and Non-arteritic Anterior Ischemic Optic Neuropathy (NAION) Oculis will launch the PIONEER Program, which includes multiple global trials intended to support registrations in AON and NAION Company to host conference call and webcast at 8:30 AM ET today Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (“Oculis”), a global biopharma",
    "url": "https://finnhub.io/api/news?id=44e935ca0078fe377bfcd4a9ad05509455b146a10844161d82e677208d93255c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759738020,
      "headline": "Oculis Accelerates Privosegtor into Registrational Trials in Acute Optic Neuritis, Pioneering the Path for a Potential First-in-class Neuroprotective Therapy",
      "id": 136989713,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AON",
      "source": "Yahoo",
      "summary": "ZUG, Switzerland, Oct. 06, 2025 (GLOBE NEWSWIRE) -- Successful meeting with FDA enables advancement into pivotal development with Privosegtor in Acute Optic Neuritis (AON) and Non-arteritic Anterior Ischemic Optic Neuropathy (NAION) Oculis will launch the PIONEER Program, which includes multiple global trials intended to support registrations in AON and NAION Company to host conference call and webcast at 8:30 AM ET today Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (“Oculis”), a global biopharma",
      "url": "https://finnhub.io/api/news?id=44e935ca0078fe377bfcd4a9ad05509455b146a10844161d82e677208d93255c"
    }
  }
]